The potential of exon skipping for treatment for Duchenne muscular dystrophy.
Duchenne muscular dystrophy is mainly caused by mutations that disrupt the generation of a translatable mRNA transcript. Most such mutations occur in parts of the gene that are not essential for its function and thus might be eliminated from the transcript to permit translation of a partially functional protein that would convert the disease to a milder clinical form. Two such antisense oligonucleotides of different backbone chemistries have been successful when tested on the mdx mouse, targeting exon 23, containing the nonsense mutation. Subsequently, the morpholino, the more effective of these, has been tested on the dystrophic dog, where it is necessary to skip 2 exons, again with beneficial results. Currently, results of 2 human trials targeting exon 51 have also yielded promising preliminary results.
Partridge
Terence
T
Genetic Medicine Research Center, Children's National Medical Center, Washington, DC 20010, USA. tpartridge@cnmcresearch.org
D000818:Animals; D002648:Child; D004285:Dogs; D016189:Dystrophin / Q000096:biosynthesis / Q000172:deficiency / Q000235:genetics*; D005091:Exons / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends; D006801:Humans; D008297:Male; D051379:Mice; D020388:Muscular Dystrophy, Duchenne / Q000235:genetics* / Q000628:therapy*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology* / Q000627:therapeutic use
D016189:Dystrophin; D016376:Oligonucleotides, Antisense